Jazz Pharmaceuticals (JAZZ) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenues ranged from $897.8M to $902M, with strong growth in Xywav (up 9% YoY) and Epidiolex (up 10% YoY), offset by oncology and Xyrem declines.

• Completed the Chimerix acquisition for $935M, adding dordaviprone to the pipeline and incurring significant IPR&D expense.

• Affirmed 2025 revenue guidance of $4.15–$4.40B, reflecting confidence in commercial portfolio and pipeline growth.

• Submitted sNDA for Zepzelca first-line maintenance in SCLC and received positive CHMP opinion for zanidatamab in advanced HER2+ BTC in the EU.

• Net loss for Q1 2025 was $92.5M, primarily due to $172M in Xyrem antitrust litigation settlements.

Financial highlights

• Xywav net product sales: $344.8M–$345M (+9% YoY); Epidiolex net product sales: $217.7M–$218M (+10% YoY).

• Oncology revenues declined 11% YoY to $229M, with Rylaze down 8% and Zepzelca down 16%.

• Operating cash flow for Q1 2025 was $429.8M–$430M; cash and investments totaled $2.6B at quarter end.

• SG&A expenses rose to $514M, driven by $172M Xyrem litigation settlements; R&D expenses decreased to $180.7M.

• Non-GAAP adjusted net income for Q1 2025 was $105M–$105.2M ($1.68 per share), down from $178M–$178.4M ($2.63) in Q1 2024.

Outlook and guidance

• 2025 revenue guidance affirmed at $4.15–$4.40B, representing 5% growth at midpoint.

• Non-GAAP net income guidance for 2025: $250M–$350M; GAAP net loss guidance: $(615)M–$(450)M.

• SG&A expected to rise in 2025 due to litigation and Chimerix integration; R&D to decrease with pipeline prioritization.

• Epidiolex expected to reach blockbuster status in 2025; Xywav remains top narcolepsy and IH therapy.

• Updated guidance reflects ~$1B impact from Chimerix acquisition and litigation settlements.